Interoperability Is Becoming the AID Competitive Moat
AID vendors are competing less on closed hardware and more on how many CGMs, pumps, and software partners they can connect into one platform.
What is this trend?
Interoperability is becoming the key competitive advantage in automated insulin delivery as companies win by connecting more CGMs, pumps, and software partners into flexible platforms.
- AID competition is shifting from closed stacks to open, partner-rich ecosystems.
- CGM breadth is now a major differentiator for pump and algorithm vendors.
- Beta Bionics, Tandem, Insulet, and Medtronic are racing to become the preferred hub.
- Interoperability lowers switching friction and expands addressable demand across sensor brands.
- Workflow and platform control are becoming more valuable than hardware lock-in.
What’s the latest?
Beta Bionics said this week that iLet Bionic Pancreas will add support for Senseonics’ Eversense 365 CGM, with the integration also planned for its future mint AID system.
How it developed
- Orchestration, compliance, and utilization are reshaping medtech value, while interoperable stacks gain ground
- Neurotherapy Competition Moves to Interoperable Workflow Stacks
Go deeper
Curated long-form picks on this trend — podcasts, videos, and analysis, by vantage.
If you operate in this industry
If you sell into this industry
AI Bot Wars Prompt Rethink of Prior Authorization in RevCycle
YouTube analysis on AI-driven prior auth, interoperable claims data, and subscription RCM strategy as the moat.
Lifers with Christina Farr · YouTube
Fuse Oncology Shows S!GNAL Integration at ASTRO 2026
Analysis featuring James Bauler on S!GNAL integration at ASTRO 2026 and interoperability as an AI revenue moat.
SaasRise · News
Read →